Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population.
about
NUDT16 is a (deoxy)inosine diphosphatase, and its deficiency induces accumulation of single-strand breaks in nuclear DNA and growth arrestImpact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infectionA disease spectrum for ITPA variation: advances in biochemical and clinical researchGLiMMPS: robust statistical model for regulatory variation of alternative splicing using RNA-seq data.Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3.Crystal structure of human inosine triphosphatase. Substrate binding and implication of the inosine triphosphatase deficiency mutation P32T.Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reductionA Prospective Study Evaluating Metabolic Capacity of Thiopurine and Associated Adverse Reactions in Japanese Patients with Inflammatory Bowel Disease (IBD).Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis CShort interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience.Pharmacogenetic significance of inosine triphosphatase.Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.ITPA (inosine triphosphate pyrophosphatase): from surveillance of nucleotide pools to human disease and pharmacogeneticsGenetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia.Modulation of mutagenesis in eukaryotes by DNA replication fork dynamics and quality of nucleotide pools.Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status.Inosine triphosphate pyrophosphatase 94C>A polymorphism: clinical implications for patients with systemic lupus erythematosus treated with azathioprine.Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection.The role of pharmacogenetics in the treatment of chronic hepatitis C infection.Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.Elevated Levels of DNA Strand Breaks Induced by a Base Analog in the Human Cell Line with the P32T ITPA Variant.The relationship between ITPA rs1127354 polymorphisms and efficacy of antiviral treatment in Northeast Chinese CHC patients.Recessive ITPA mutations cause an early infantile encephalopathy.Quantitative in vitro and in vivo characterization of the human P32T mutant ITPase.ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response.Gene polymorphisms involved in manifestation of leucopenia, digestive intolerance, and pancreatitis in azathioprine-treated patients.ITPase-deficient mice show growth retardation and die before weaning.Erythrocyte Inosine triphosphatase activity: A potential biomarker for adverse events during combination antiretroviral therapy for HIV.Efficacy of splenectomy in preventing anemia in patients with recurrent hepatitis C following liver transplantation is not dependent on inosine triphosphate pyrophosphatase genotype.Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens.Inosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C VirusEvolving Trends in the Hepatitis C Virus Molecular Epidemiology Studies: From the Viral Sequences to the Human Genome
P2860
Q24306490-EA307427-F5D4-46FB-A5E8-972953DBA95AQ26801381-599C2108-746D-4689-95FE-D2D200ADC887Q28069352-FBF08D3D-5465-435F-BACE-B0C6E9363A82Q30656680-06F9D63D-DD69-4FFB-9D9D-B832498945BEQ33395929-EEFDCA9D-44D9-4933-AE65-FFA1DC71CD60Q33413296-91950284-D84E-4014-B102-40BCF258DD72Q34586219-467F4126-46B3-45FF-91C0-ACA0B2E46664Q34913385-6220B203-4DF4-43E4-99D4-D87C51A42C7EQ35770480-ECC6F070-3899-41E5-BBC7-07F970EB5AC8Q36018931-E1E3A3E1-0076-4DE3-AB5E-6FC7C87815AEQ36059685-3E2AA321-B49B-4DF5-B2B4-76813A81EF98Q36519135-A1DBBC1C-1329-4241-83DE-43FED26B3418Q36966047-C4F863A3-9EA8-4FE9-B24D-2CF006125A91Q36967047-805A8A58-B842-41F7-BB4E-A476E2C2288CQ37308142-DB902157-AC08-4836-A4B8-C61D79CB02A5Q37388537-B80109C2-E365-4101-A8DF-6A4A5BC0D1EEQ37483304-DFEF5DD8-F09F-4522-954A-24D16BE50C80Q37658863-FD63ADB6-5981-4042-960A-B49E15A8CEF2Q37724360-A3C368C6-887F-46FA-812F-7DB1565F588BQ37879701-5FF8CF23-4326-48B1-AA77-755BC672C164Q38151586-A58ADF93-2701-411E-B7C4-EFF527834100Q38417177-634660C0-1E07-43F3-B1CC-5F2F04BAB7B2Q39645960-1D852710-B662-4B61-89F9-7F9A05A89429Q40116569-A4C5027C-9A78-4A58-AEDE-1B177E18D965Q41927690-5D417A30-B0C5-42F6-BCE6-7691DF08AC58Q42174246-1C9C085E-FCDF-4CF8-8132-A2E26F5FEC80Q42223359-34518D5A-8033-4774-A363-087DB7E8AD96Q42241980-63EC377C-A26F-4B1D-9B27-F8D7C0DEA739Q42718640-7C7EB58A-436A-4C87-AC43-5E276E577122Q45981845-A34C2D33-57C8-45AB-AC3F-E8A1AEE7D4CDQ47554338-18550AC7-8C37-4D43-883D-0231AFC542F7Q50554056-95D398D1-8A6F-475C-9AA0-B490FE8DBACAQ50557485-75769C29-A150-4A23-AE94-E4BB97FA7123Q55427239-88F20BD6-B543-4F77-B52A-8DEBD97634A9Q58682726-027AC02B-C451-4157-B8C1-8CCD1676BABAQ58701375-07E28706-7681-4A5E-A447-3841E5DFF2CE
P2860
Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Genetic basis of inosine triph ...... cy in the Japanese population.
@ast
Genetic basis of inosine triph ...... cy in the Japanese population.
@en
Genetic basis of inosine triph ...... cy in the Japanese population.
@nl
type
label
Genetic basis of inosine triph ...... cy in the Japanese population.
@ast
Genetic basis of inosine triph ...... cy in the Japanese population.
@en
Genetic basis of inosine triph ...... cy in the Japanese population.
@nl
prefLabel
Genetic basis of inosine triph ...... cy in the Japanese population.
@ast
Genetic basis of inosine triph ...... cy in the Japanese population.
@en
Genetic basis of inosine triph ...... cy in the Japanese population.
@nl
P2093
P1476
Genetic basis of inosine triph ...... cy in the Japanese population.
@en
P2093
Akihito Ueta
Anthony M Marinaki
Hajime Togari
Satoshi Sumi
Shinsaku Hasegawa
Tetsuya Ito
Tohru Maeda
Yukihisa Kurono
Yumiko Ohkubo
P304
P356
10.1016/J.YMGME.2005.03.011
P577
2005-08-01T00:00:00Z